July 2, 2026
10:09 pm

How Health Affects Life Settlement Value

Health is the single largest driver of a life settlement offer: the more an insured’s medical conditions shorten their underwritten life expectancy, the fewer premiums the buyer expects to pay and the sooner it expects to collect — so the offer rises, often dramatically. Two insureds of identical age with identical policies can receive offers that differ by multiples based on their medical files alone. At the far end of the spectrum, a terminal diagnosis with life expectancy under 24 months converts the sale into a viatical settlement, where proceeds are often income-tax-free under IRC 101(g) and the carrier’s accelerated death benefit should be checked first.

Here is how underwriters translate diagnoses into dollars — impairment by impairment — and what sellers can do to make sure their health is priced accurately rather than optimistically.

In This Article

The Pricing Machine: From Medical Chart to Dollar Offer
Debits and Credits: How Underwriters Score a Medical File
A Tour of the Impairment Spectrum
The Healthy-Insured Problem — and Its Mirror Image
Where Health Changes the Law, Not Just the Price: The Viatical Threshold
Documentation: The Difference Between Your Health and Your Priced Health
Reading Offers Through the Health Lens: A Seller’s Checklist
Frequently Asked Questions

How Health Affects Life Settlement Value

The Pricing Machine: From Medical Chart to Dollar Offer

To see why health dominates settlement value, follow a policy through a buyer’s model.

A licensed provider values a policy as a discounted cash flow: money out (every future premium needed to keep the policy in force) versus money in (the death benefit, received when the insured passes away), discounted at the institutional buyer’s required rate of return. Three inputs decide everything — premium schedule, discount rate, and the timing assumption for the death benefit. The first two are relatively fixed features of the policy and the capital markets. The third is the insured’s life expectancy, and it is almost entirely a health question.

Shorten life expectancy and both sides of the ledger improve for the buyer: fewer premium payments go out, and the death benefit arrives sooner, where discounting punishes it less. That is the entire mechanism by which a diagnosis becomes a dollar figure. It also explains the market’s structure, documented in the GAO’s report on life settlements: offers spanning roughly 10–35% of face value and averaging four to eight times cash surrender value, with position inside that band driven principally by underwritten mortality.

A concrete illustration: on a $500,000 universal life policy with meaningful annual premiums, moving the underwritten life expectancy from twelve years to six can turn a decline into a competitive offer, and from six years to two can multiply the offer again. The precise mathematics of that curve — and why offers rise faster than linearly as life expectancy falls — is the subject of our companion piece, life expectancy and settlement pricing.

Debits and Credits: How Underwriters Score a Medical File

The translation from chart to life expectancy happens at specialized underwriting firms that produce independent life expectancy reports — typically two per transaction, taking two to six weeks. Their method matters to sellers because it reveals what actually moves value.

Underwriters begin with a baseline mortality table for the insured’s age and sex, then apply debits — multipliers that increase assumed mortality — for each documented impairment, and credits for favorable factors (excellent functional status, strong family longevity, well-controlled conditions). The output is a personalized survival curve, usually summarized as a median life expectancy in months.

Key features of the scoring that surprise sellers:

Combinations compound. Heart failure alone is a debit; heart failure plus chronic kidney disease plus COPD multiplies, because the conditions interact. Multi-system illness moves estimates more than the sum of its parts.
Severity beats labels. “Diabetes” barely registers; diabetes with neuropathy, nephropathy, and an amputation registers heavily. Underwriters price staging, lab values, imaging findings, and complications — not diagnosis names.
Function is a first-class input. Assistance with activities of daily living, mobility aids, unintentional weight loss, falls, and hospitalization frequency are among the strongest mortality predictors in older insureds — often outweighing any single diagnosis.
Control cuts both ways. A condition managed into stability earns smaller debits. Documented treatment failure or progression earns larger ones.

Because firms weight impairments differently, the two reports on a file rarely match; buyers commonly average them or lean conservative. Sellers cannot choose the methodology — but they control the completeness of the file it runs on, which the final section addresses.

A Tour of the Impairment Spectrum

While every file is individual, underwriting experience shows how the major condition categories tend to influence value:

Cardiovascular disease. The spectrum is wide: stable, stented coronary disease adds modest debits, while congestive heart failure — particularly with reduced ejection fraction, repeat hospitalizations, or defibrillator placement — is among the most value-relevant common diagnoses.
Pulmonary disease. COPD staged by pulmonary function tests scales cleanly in mortality models; oxygen dependence and pulmonary fibrosis carry heavy weight.
Cancer. The most situation-dependent category. A treated, distant early-stage cancer may add almost nothing; active treatment, recurrence, or metastasis can shift a file entirely out of ordinary settlement pricing and into viatical territory.
Neurological and cognitive disease. Dementia staging is heavily weighted — advanced Alzheimer’s disease materially shortens estimates — as are Parkinson’s with falls or swallowing involvement, post-stroke deficits, and ALS.
Renal disease. Staged chronic kidney disease scales steadily; dialysis dependence is one of the strongest single debits in the book.
Diabetes. Value-relevant in proportion to its complications and duration, not its presence.
Frailty syndromes. In insureds over 80, weight loss, sarcopenia, falls, and ADL dependence frequently matter more than any organ-specific diagnosis.

The broader qualification picture — including how significant impairments allow insureds younger than 65 to qualify at all — is covered in life settlements with a serious health condition.

Illustrative Health Profile (age 75, $500,000 UL policy)	Typical Underwritten LE	Pricing Tendency	Classification
Excellent health, no significant impairments	~13–17 years	Often no offer above surrender value	Ordinary life settlement (if marketable)
Single stable impairment (stented CAD, controlled diabetes)	~10–13 years	Low end of the 10–35% of face range	Ordinary life settlement
Multiple significant impairments (CHF + CKD stage 4 + COPD)	~5–8 years	Mid-to-upper range; 4–8× surrender value typical	Impaired life settlement
Severe impairment with functional decline (advanced dementia, 2+ ADL deficits)	~3–5 years	Upper range	Often chronic-illness viatical under state law
Terminal certification (metastatic cancer, end-stage organ failure)	Under 24 months	Can exceed the standard range; state minimums may apply	Viatical settlement; IRC 101(g) exclusion often applies

The Healthy-Insured Problem — and Its Mirror Image

Health’s dominance in pricing produces two situations sellers should understand before forming expectations.

The healthy insured. A 70-year-old in excellent health underwrites to a long life expectancy — often 15-plus years. The buyer facing that horizon must fund many premiums and wait long for a heavily discounted death benefit, so offers come in low or not at all; many perfectly good policies on healthy insureds simply do not price above cash surrender value. For those policyholders, the honest comparison is often settlement versus surrender or holding the policy — and if premiums are the pressure point, the premium-hardship options deserve a look before any sale at a disappointing price.

The mirror image: health changes after issue. The seller for whom the market works best is typically someone whose health declined after the policy was purchased. The carrier priced the policy on the insured’s health at issue; the settlement market prices it on health today. That gap — insured at standard rates, now carrying significant impairments — is precisely where offers reach four to eight times surrender value and beyond. A major health event is, bluntly, a repricing event for the policy.

Two implications follow. First, a settlement quote from years ago is stale the moment health changes; files are worth re-underwriting after significant diagnoses. Second, sellers should be wary of anyone quoting a value before underwriting — without the medical file, a number is a marketing device, not an offer. Genuine pricing always follows the life expectancy reports, and competition among multiple licensed bidders is what pushes it toward fair value.

Where Health Changes the Law, Not Just the Price: The Viatical Threshold

Up to a point, declining health just moves a policy along the pricing curve. At a legally defined threshold, it changes the transaction’s entire framework.

When a physician certifies terminal illness — an illness or condition reasonably expected to result in death within 24 months — or a practitioner certifies chronic illness (inability to perform two or more activities of daily living, or severe cognitive impairment requiring supervision), the sale becomes a viatical settlement under most state laws, modeled on the NAIC framework. Three consequences follow:

Taxes transform. Ordinary settlement proceeds face the three-tier treatment of IRS Rev. Rul. 2009-13 (basis tax-free; basis-to-CSV ordinary income; remainder capital gain). Terminal-illness viatical proceeds, by contrast, are often entirely income-tax-free under IRC 101(g); chronic-illness proceeds receive conditional relief tied to long-term care costs. Details in the viatical tax exclusion guide.
Pricing floors appear. Several states mandate minimum viatical payouts as a percentage of face value, scaled to life expectancy bands.
Age exits the analysis. Viatical qualification is diagnosis-driven; a 45-year-old can qualify — see who qualifies for a viatical settlement.

The threshold also triggers a mandatory comparison: policies frequently contain accelerated death benefit riders paying on the very same terminal or chronic triggers — directly from the carrier, faster, and with the unaccelerated remainder preserved for beneficiaries. State disclosure law requires sellers be told of this alternative; prudence requires actually pricing it before signing anything.

Documentation: The Difference Between Your Health and Your Priced Health

A crucial distinction runs through every settlement: the market does not price your health — it prices your documented health. The gap between the two is where sellers most often leave money on the table.

Life expectancy underwriters work exclusively from records obtained under the HIPAA authorizations signed at intake (see what those releases cover). Anything absent from the records is absent from the model:

The stoic-patient penalty. Insureds who rarely see doctors generate thin charts. Thin charts produce few debits, long life expectancy estimates, and low offers — regardless of actual health. If it has been a year since your last specialist visit, a current examination that documents present status is the single highest-yield preparation step.
The functional-status blind spot. Physicians document diagnoses reliably but often under-record function: who helps with bathing and dressing, walker or wheelchair use, weight trajectory, falls, paid caregiver hours. These are heavily weighted mortality inputs — ask your physician to note them explicitly.
Recency discounting. Old records carry less weight. Progression documented last quarter outprices progression last documented three years ago.
Completeness across providers. Cardiology, nephrology, oncology, primary care — each chart holds different debits. A provider list assembled on day one, with records requested in parallel, both speeds the 60–120 day process and ensures no impairment is missed.

None of this is gaming the system; it is making the record match reality so the price does too. Sellers should also verify every counterparty’s license with their state insurance department — in New Jersey, the Department of Banking and Insurance — and remember that offers are only comparable after fees, taxes, and any public-benefits impact, a framework laid out in our complete guide.

Reading Offers Through the Health Lens: A Seller’s Checklist

Health explains most of the variance between settlement offers — which makes it the right lens for evaluating them. Before accepting any offer, work through this sequence:

Do the life expectancy reports look like your medical reality? You are entitled to understand the estimates driving your offers. If the reports assume a healthier person than the one in the mirror — because records were thin or stale — fix the file and re-underwrite rather than accept a mispriced offer.
Is the transaction classified correctly? If your facts support terminal or chronic certification, the sale should be a viatical with its tax and pricing-floor advantages — not an ordinary settlement. Do not let classification default; it is worth real money.
Has the carrier’s ADB been quoted in writing? For terminal and chronic cases, the rider may beat the market — and it preserves part of the death benefit for family.
Is there genuine competition? A single offer reveals nothing about value. Multiple licensed providers bidding on the same underwritten file is the only reliable price-discovery mechanism; brokers should disclose compensation in dollars.
What does the after-everything net look like? Compare paths on net proceeds after fees and taxes, and after modeling any effect on Medicaid or SSI eligibility — a lump sum is a countable asset, and the sequencing rules in our Medicaid spend-down guide can matter more than the gross price.
Does holding beat selling? The sicker the insured, the closer the death benefit — the same fact that raises offers also raises the value of keeping the policy for beneficiaries, if premiums are sustainable.

The rescission window — 15 to 30 days depending on the state — exists as a final backstop for exactly this review. Use the time; the decision is permanent afterward.

Frequently Asked Questions

Why does worse health mean a higher life settlement offer?

Because the buyer’s economics run on life expectancy. A provider purchasing your policy commits to paying every future premium and waits for the death benefit. When health conditions shorten the underwritten life expectancy, the buyer funds fewer premiums and collects sooner — both of which raise what it can pay you today. That is why offers documented by the GAO span roughly 10–35% of face value, with the insured’s medical file largely determining where a policy lands.

How much more is a life settlement worth with serious health problems?

There is no fixed multiplier, but the direction and rough scale are consistent: healthy insureds often receive no offer above surrender value, single stable impairments price near the bottom of the range, multi-system disease prices mid-to-upper range at typically four to eight times cash surrender value, and terminal certifications can exceed the standard 10–35% of face entirely. The honest answer for any specific policy requires underwriting and competitive bids — be skeptical of anyone quoting numbers before seeing medical records.

What medical conditions do life settlement underwriters weight most heavily?

Congestive heart failure with reduced ejection fraction, oxygen-dependent COPD and pulmonary fibrosis, dialysis-dependent kidney disease, active or metastatic cancer, advanced dementia, ALS, and — especially — combinations of impairments across organ systems, which compound in mortality models. In insureds over 80, frailty markers like unintentional weight loss, falls, and needing help with activities of daily living often outweigh any single diagnosis. Severity, progression, and functional impact drive the scoring; diagnosis labels alone move little.

Can my life settlement offer go up if my health gets worse after I get a quote?

Yes. Settlement pricing reflects health at the time of underwriting, so a significant new diagnosis, hospitalization, or documented progression is effectively a repricing event for your policy. Old quotes go stale the moment the medical picture changes. If your health has declined materially since a prior evaluation — or since you declined an earlier offer — the file is worth re-underwriting with fresh records. The same logic runs in reverse: pricing is never locked until a contract closes.

Do I need to see a doctor before applying for a life settlement?

It is one of the highest-value preparation steps. Underwriters price only what the records document, and thin or stale charts systematically understate impairment — producing longer life expectancy estimates and lower offers. A current visit with your primary physician and relevant specialists that documents present status, staging, lab values, and especially functional limitations (ADL assistance, mobility aids, weight trends, falls) makes the file match reality. Sellers who avoid doctors are, in pricing terms, penalized for their stoicism.

What is the difference between how health affects a life settlement versus a viatical settlement?

In an ordinary life settlement, health is a pricing input: worse documented health means shorter life expectancy and a higher offer along a continuous curve. At a legal threshold — physician-certified life expectancy under 24 months, or chronic illness with two-plus ADL deficits — the transaction becomes a viatical settlement, which changes the framework itself: several states impose minimum payout percentages, age requirements disappear, and proceeds for terminally ill sellers are often fully income-tax-free under IRC 101(g).

Why did I get very different offers from two life settlement companies?

Usually because they relied on different life expectancy estimates or different return requirements. The two independent LE reports on a file rarely match — underwriting firms weight impairments differently — and buyers vary in how they blend them and in their cost of capital. Divergent offers are precisely why competition matters: a single bid tells you nothing about fair value. Ask what life expectancy each offer assumes, make sure your records were complete, and let multiple licensed providers bid.

Does health affect the taxes on a life settlement?

Substantially, at the extremes. An ordinary settlement — regardless of impairment level — follows Rev. Rul. 2009-13’s three tiers: tax-free up to basis, ordinary income from basis to cash surrender value, capital gain above. But a physician certification of terminal illness (life expectancy under 24 months) generally makes viatical proceeds fully income-tax-free under IRC 101(g), and chronic-illness certification earns conditional relief tied to long-term care costs. Getting the classification right, in writing, can be worth more than a better gross offer.

Find out what your policy is worth — free, confidential, no obligation.

A 15-minute educational review covers your eligibility, every alternative, and a realistic view of what each path would net you.

Call (305) 209-7183 · Request a review online →

Table of Contents